Amniotic epithelial cell

Amniotic epithelial cells have the ability to develop into any of the three germ layers: endoderm, mesoderm, and ectoderm.

They can develop into several organ tissues specific to these germ layers including heart, brain, and liver.

Amniotic epithelial cells have shown to be safe and successfully transplanted into hosts that are not related to the donor.

One possible reason for this is that amniotic epithelial cells have low antigen levels that inhibit compatibility from a donor to the recipient.

Also, amniotic epithelial cells are known to promote natural wound healing as well as the inhibition of angiogenesis, which is the basic conversion of a tumor into malignant cancer.

There have been several studies conducted on the potential benefits of using amniotic epithelial cells in various parts of the body.

More specifically, amniotic epithelial cells have been used in the past to treat genetic liver diseases such as ornithine transcarbamylase deficiency, familial hypercholesterolemia, and Crigler–Najjar syndrome.

Scientists are also working with genetically modified human amniotic epithelial cells in new experimental procedures and cellular therapies.

Also, amniotic epithelial cells have shown potential for encouraging tissue repair of the recipient.

Studies have shown that the use of amniotic epithelial cells in cellular therapies involving spinal cord injuries is promising because of their ability to differentiate into fully operational neurons and can release neurotransmitters.

Amniotic epithelial cells have also shown positive effects when used to treat severe burn victims by encouraging tissue repair of the recipient as well as treatment for certain autoimmune diseases.

Scientists have recently discovered that human amniotic epithelial cells are able to produce and release the plasma protein albumin.